Paraplegia News and Research

RSS

Paraplegia is an impairment in motor or sensory function of the lower extremities. It is usually the result of spinal cord injury or a congenital condition such as spina bifida which affects the neural elements of the spinal canal.

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Neuralstem signs definitive agreements to sell $10M of units in registered-direct offering

Neuralstem, Inc. announced today that it has entered into definitive agreements to sell $10 million of units at $2.80 per unit in a registered-direct offering to institutional investors. The units consist of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years.

25 Jun 2010

New study data on distal aortic perfusion for thoracoabdominal aortic aneurysm repair

The vascular surgeons at Massachusetts General Hospital (MGH) in Boston have traditionally repaired thoracoabdominal aortic aneurysms (TAA) with a clamp and sew (CS) technique that includes neuro-protective adjuncts like epidural cooling and aggressive intercostal reconstruction (IC) to prevent spinal cord ischemia.

11 Jun 2010

Neuralstem updates progress of ongoing Phase I human clinical trial for ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient.

25 May 2010

Neuralstem's stem cell treatment for ALS featured on CNN with Dr. Sanjay Gupta

Neuralstem, Inc. announced that its stem cell treatment for ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease), currently in a FDA-approved Phase I clinical trial, was featured on CNN last night with Dr. Sanjay Gupta, in the piece entitled "Stem Cell Medical Breakthrough".

30 Apr 2010

Neuralstem raises $5.25M, also receives NYSE Amex compliance notice

Neuralstem, Inc. announced today that it has raised a total of $5,228,000 since the beginning of the year, comprised of a previously disclosed $1.5 million private placement of 646,551 common shares at $2.32, priced at a 30 percent premium over the market on the closing, and approximately $3.7 million from warrant exercises.

19 Feb 2010

Neuralstem announces treatment of first ALS patient with spinal cord stem cells

Neuralstem, Inc. announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.

21 Jan 2010

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

Neuralstem, Inc. today announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA.

19 Dec 2009

Hemicorporectomy effective, and add years and quality of life to survivors

A landmark, 25-year review of cases in which surgeons had to remove the lower portion of the body from the waist down for severe pelvic bone infections shows the therapy can add years and quality of life to survivors, say researchers at UT Southwestern Medical Center.

20 Nov 2009

Neuralstem provides financial and business updates for third-quarter 2009

Neuralstem, Inc. today provided a financial and business update for the third quarter ended September 30, 2009.

17 Nov 2009

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.

21 Sep 2009

Neuralstem's patent on neural stem cell transplantation approved

Neuralstem, Inc. today announced that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent entitled “Transplantation of Human Neural Cells For Treatment Of Neurodegenerative Conditions,” number 11/281,640.

9 Sep 2009

Possible neurological complications of heart surgery detailed in new report

In the most comprehensive and up-to-date review of its kind, researchers list possible nervous system complications of bypass surgeries, aortic surgery, cardiac catheterizations, valve replacements, heart transplants and surgeries for congenital heart disease and heart tumors.

13 Aug 2009

Neurological complications of heart surgery detailed in research

Possible neurological complications of heart surgery, ranging from headaches to strokes, are detailed in a new report in the online journal MedLink Neurology.

13 Aug 2009

Epidurals and spinal anesthetics safer than previously reported

The largest ever prospective study [1,2] into the major complications [3] of epidurals and spinal anaesthetics published in the British Journal of Anaesthesia today (Monday 12 January 2009) concludes that previous studies have over-estimated the risks of severe complications of these procedures.

12 Jan 2009

Neuralstem files IND for amyotrophic lateral sclerosis stem cell trial

Neuralstem, Inc. announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

18 Dec 2008

Neuralstem enters stem cell collaboration for Huntington's disease in Germany

Neuralstem, Inc. announced today that it has entered into a collaboration with Professor Guido Nikkah Ph.D, of Albert-Ludwigs-University in Freiburg, Germany, to advance development of Neuralstem's human neural stem cell therapies.

18 Nov 2008

Gene find sheds light on motor neuron diseases like amyotrophic lateral sclerosis

Scientists have identified a gene in mice that plays a central role in the proper development of one of the nerve cells that goes bad in amyotrophic lateral sclerosis, or Lou Gehrig's disease, and some other diseases that affect our motor neurons.

22 Oct 2008

Campaign focuses on hereditary spastic paraplegia

A campaign to raise awareness of Hereditary Spastic Paraplegia (HSP) and announce a world first test for the little known genetic neurological disorder will be launched today by researchers at Sydney University's ANZAC Research Institute.

7 Apr 2008

New therapy for chronic spasticity and rigidity

Research led by scientists at the University of California, San Diego (UCSD) School of Medicine has identified a target with potential as an effective new therapy for chronic spasticity and rigidity, a painful condition that often results from spinal cord injury.

17 Oct 2007